Clinical Trial Update: TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial updating TAS-102 combined with irinotecan in second-line or higher gastric and gastroesophageal adenocarcinoma; study completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: University of California, Irvine | Conditions: Gastric Adenocarcinoma, GastroEsophageal Cancer | Phase 1 | Status: COMPLETED | Results posted: 2024-02-02